The objective of this study was to explore what non-pharmacological interventions have been examined for individuals with antiphospholipid syndrome (APS).
Methods
We conducted a systematic literature search of the databases PubMed, Embase, Scopus, Web of Science, CINAHL, and ClinicalTrials.gov from 1983–Feb. 2023. Our scoping review included studies that examined non-pharmacological interventions for individuals with APS using patient-reported outcome measures. We excluded studies that reported physiological outcomes only.
Results
The review yielded one case study on the safety and efficacy of an exercise program for a 15-year-old male with secondary APS using physiological and patient-reported outcome measures. Despite the lack of evidence of non-pharmacological interventions for individuals with APS, one excluded study reported that individuals with APS want guidance about physical activity and exercise. We also found several types of potentially relevant non-pharmacological interventions for individuals with lupus, a disease that often co-occurs with APS.
Conclusions
Non-pharmacological interventions may offer a solution for addressing some non-thrombotic or non-obstetric APS symptoms, such as neurological, physical, and cognitive symptoms that are not well-controlled by anticoagulation. Due to the unique risks associated with APS, research is needed to determine the safety and efficacy of non-pharmacological interventions, particularly those involving exercise. Adopting a comprehensive, multidisciplinary approach to managing patients with APS and involving rehabilitation professionals, who are experts in the design and delivery of non-pharmacological interventions, may provide a foundation for developing and testing novel interventions that improve health outcomes while also fulfilling unmet needs reported by patients.
KnightJSBranchDWOrtelTL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ2023; 380: e069717.
2.
DabitJYValenzuela-AlmadaMOVallejo-RamosS, et al.Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep2022; 23(12): 85.
3.
HwangJJShinSHKimYJ, et al.Epidemiology of antiphospholipid syndrome in Korea: a nationwide population-based study. J Kor Med Sci2020; 35(5): e35.
4.
Klein HaneveldMJLemmenCHCBrunekreefTEARCH Study Group, et al.Diagnosis and treatment of patients with antiphospholipid syndrome: a mixed-method evaluation of care in The Netherlands. Rheumatol Adv Pract2020; 4(2): rkaa021.
5.
SammaritanoLR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol2020; 34(1): 101463.
6.
SciasciaSAmigoMCRoccatelloD, et al.Diagnosing antiphospholipid syndrome: “extra-criteria” manifestations and technical advances. Nat Rev Rheumatol2017; 13(9): 548–560.
ArnsonYShoenfeldYAlonE, et al.The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum2010; 40(2): 97–108.
10.
TektonidouMGVarsouNKotoulasG, et al.Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med2006; 166(20): 2278–2284.
11.
YelnikCMKozoraEAppenzellerS. Cognitive disorders and antiphospholipid antibodies. Autoimmun Rev2016; 15(12): 1193–1198.
12.
SevimEZisaDAndradeDAPS ACTION Investigators, et al.Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository. Arthritis Care Res2022; 74(2): 324–335.
13.
PanopoulosSThomasKGeorgiopoulosG, et al.Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study. Rheumatology2020; 60(1): 170–178.
14.
GeorgopoulouSEfraimidouSMacLennanSJ, et al.Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus2015; 24(2): 174–179.
15.
SpyropoulouACTsartsaraEIAngelopoulouA, et al.Psychiatric manifestations preceding fetal death in antiphospholipid syndrome. Gen Hosp Psychiatr2010; 32(2): 225–227.
16.
BrierN. Understanding and managing the emotional reactions to a miscarriage. Obstet Gynecol1999; 93(1): 151–155.
17.
BearneLMBielesJGeorgopoulouS, et al.Fatigue in adults with primary antiphospholipid syndrome: findings from a mixed-methods study. Lupus2020; 29(8): 924–933.
18.
KhairaniCDBejjaniAPiazzaG, et al.Direct oral anticoagulants vs vitamin K antagonists in patients With Antiphospholipid syndromes: meta-analysis of randomized trials. J Am Coll Cardiol2023; 81(1): 16–30.
19.
CapecchiMAbbattistaMCiavarellaA, et al.Anticoagulant therapy in patients with antiphospholipid syndrome. J Clin Med2022; 11(23): 6984.
20.
PengoVHoxhaAAndreoliL, et al.Trial of rivaroxaban in AntiPhospholipid syndrome (TRAPS): two‐year outcomes after the study closure. J Thromb Haemostasis2021; 19(2): 531–535.
21.
GarciaDErkanD. Diagnosis and management of the antiphospholipid syndrome. Longo DL, editor. N Engl J Med2018; 378(21): 2010–2021.
22.
Hernández-MolinaGGonzález-PérezIPacheco-MolinaC, et al.Quality of life in patients with antiphospholipid syndrome is related to disease burden and anticoagulant therapy. Int J Rheum Dis2017; 20(6): 755–759.
23.
ChangAWinquistNWWescottAB, et al.Systematic review of digital and non-digital non-pharmacological interventions that target quality of life and psychological outcomes in adults with systemic lupus erythematosus. Lupus2021; 30(7): 1058–1077.
24.
FangthamMKasturiSBannuruRR, et al.Non-pharmacologic therapies for systemic lupus erythematosus. Lupus2019; 28(6): 703–712.
25.
RolvingNBrockiBCAndreasenJ. Coping with everyday life and physical activity in the aftermath of an acute pulmonary embolism: a qualitative study exploring patients’ perceptions and coping strategies. Thromb Res2019; 182: 185–191.
26.
HamblyK. SP0078 the patients perspective on physical activity and work participation in rmds. In: THURSDAY, 14 JUNE 2018. London: BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. p. 21.2. Available from:https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-eular.7700
27.
FischerSMeisingerCLinseisenJ, et al.Depression and anxiety up to two years after acute pulmonary embolism: prevalence and predictors. Thromb Res2023; 222: 68–74.
28.
Spencer-TansleyRMeadeNAliF, et al.Mental health care for rare disease in the UK – recommendations from a quantitative survey and multi-stakeholder workshop. BMC Health Serv Res2022; 22(1): 648.
29.
JaegerGRöjvikABerglundB. Participation in society for people with a rare diagnosis. Disabil Health J2015; 8(1): 44–50.
30.
ArkseyHO’MalleyL. Scoping studies: towards a methodological framework. Int J Soc Res Methodol2005; 8(1): 19–32.
31.
TriccoACLillieEZarinW, et al.PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med2018; 169(7): 467–473.
32.
LevacDColquhounHO’BrienKK. Scoping studies: advancing the methodology. Implement Sci2010; 5(1): 69.
33.
ClarkJMSandersSCarterM, et al.Improving the translation of search strategies using the polyglot search translator: a randomized controlled trial. J Med Libr Assoc2020; 108(2): 195–207. Available from:https://jmla.pitt.edu/ojs/jmla/article/view/834
34.
BramerWMGiustiniDDe JongeGB, et al.De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc2016; 104(3): 240–243. Available from:https://jmla.pitt.edu/ojs/jmla/article/view/24
35.
TriccoACLillieEZarinW, et al.A scoping review on the conduct and reporting of scoping reviews. BMC Med Res Methodol2016; 16(1): 15.
36.
BlackN. Patient reported outcome measures could help transform healthcare. BMJ2013; 346(jan28 1): f167–f167.
37.
CianiOFedericiCB. Value lies in the eye of the patients: the why, what, and how of patient-reported outcomes measures. Clin Therapeut2020; 42(1): 25–33.
38.
HughesGR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. BMJ1983; 287(6399): 1088–1089.
39.
Center for Evidence Based Management. Critical appraisal checklist for a case study. Leiden: Center for Evidence Based Management, 2014. Available from: https://www.cebma.org
40.
OdedunRKumarRMcCannL. G315(P) Treatment of anticardiolipin antibody mediated chorea in an adolescent male. In: British paediatric neurology association. London: BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2018, p. A128.2. Available from: https://adc.bmj.com/lookup/doi/10.1136/archdischild-2018-rcpch.306
41.
GarciaCBSeguroLPCPerandiniLA, et al.Acute physical exercise is safe in patients with primary antiphospholipid syndrome with exclusive venous thrombosis and under oral anticoagulation with warfarin. Rheumatol Int2014; 34(12): 1737–1741.
42.
GarciaCPerandiniLSeguroL, et al.Impaired aerobic exercise capacity and cardiac autonomic control in primary antiphospholipid syndrome. Lupus2013; 22(9): 928–931.
43.
GarciaCBMatosLNJNegraoCE, et al. Effects of maximal acute physical exercise on prothrombin time in patients with primary antiphospholipid syndrome (PAPS) under oral anticoagulation with warfarin and exercise capacity. Arthritis Rheum. 2011; 63(10 (Suppl)): S614.
44.
HamblyK. FRI0576-HPR exercise participation in people with antiphospholipid syndrome: associations with exercise self-efficacy and illness perception. Ann Rheum Dis2014; 73(Suppl 2): 1203.2.
45.
PradoDMGualanoBPintoALS, et al.Exercise in a child with systemic lupus erythematosus and antiphospholipid syndrome. Med Sci Sports Exerc2011; 43(12): 2221–2223.
46.
GoorahDHurlongSKCasellaGT. Poster 297 exercise induced spinal cord infarct (EISCI) in a young male with antiphospholipid syndrome (APS): a case report of a workman’s compensation (WC) case litigation. PM&R2016; 8(9S): S257. Available from:https://onlinelibrary.wiley.com/doi/10.1016/j.pmrj.2016.07.469
47.
Riancho-ZarrabeitiaLMartínez-TaboadaVRúa-FigueroaI, et al.Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus2020; 29(12): 1556–1565.
48.
Ruiz-IrastorzaGEgurbideMVUgaldeJ, et al.High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med2004; 164(1): 77–82.
49.
O’DwyerTDurcanLWilsonF. Exercise and physical activity in systemic lupus erythematosus: a systematic review with meta-analyses. Semin Arthritis Rheum2017; 47(2): 204–215.
50.
GašperšičNZaletelMKobalJ, et al.Stroke and antiphospholipid syndrome—antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event. Clin Rheumatol2019; 38(2): 379–384.
51.
DenasGJoseSPBraccoA, et al.Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev2015; 14(3): 214–222.
52.
TenediosFErkanDLockshinMD. Cardiac involvement in the antiphospholipid syndrome. Lupus2005; 14(9): 691–696.
53.
TektonidouMG. Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis. J Autoimmun2022; 128: 102813.
54.
YelnikCMRicheyMHaiducV, et al.Cardiovascular disease prevention counseling program for systemic lupus erythematosus patients. Arthritis Care Res2017; 69(8): 1209–1216.
55.
SpringNHBernsteinEKimSJ, et al.Utilizing Facebook chats to convey health information to lupus patients at the systemic lupus erythematosus-antiphospholipid syndrome center of excellence at hospital for special surgery. In: Arthritis and rheumatism. San Diego, CA: Wiley-Blackwell, 2013, p. S422.
56.
WilliamsEMEgedeLFaithT, et al.Effective self-management interventions for patients with lupus: potential impact of peer mentoring. Am J Med Sci2017; 353(6): 580–592.
57.
FreedenbergVAThomasSAFriedmannE. A pilot study of a mindfulness based stress reduction program in adolescents with implantable cardioverter defibrillators or pacemakers. Pediatr Cardiol2015; 36(4): 786–795.
58.
American Occupational Therapy Association. Occupational therapy practice framework: domain and process—fourth edition. Am J Occup Ther. 2020; 74(Supplement_2): 7412410010p1–87.
59.
American Physical Therapy Association. APTA Guide to Physical Therapist Practice 4.0. Alexandria, VA: APTA, 2023. Available from:https://guide.apta.org/
60.
American Speech-Language-HearingAssociation.Scope of practice in speech language pathology [Scope of Practice], 2016. Available from:www.asha.org/policy/
61.
AmbrosettiMAbreuACorràU, et al.Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the secondary prevention and rehabilitation section of the European association of preventive cardiology. Eur J Prev Cardiol2021; 28(5): 460–495.
62.
PattiAMerloLAmbrosettiM, et al.Exercise-based cardiac rehabilitation programs in heart failure patients. Heart Fail Clin2021; 17(2): 263–271.
63.
MacKay-LyonsMBillingerSAEngJJ, et al.Aerobic exercise recommendations to optimize best practices in care after stroke: AEROBICS 2019 update. Phys Ther2020; 100(1): 149–156.
64.
PintoSMYassinMGalangG. Cost-effectiveness analysis of routine venous Doppler ultrasound for diagnosis of deep venous thrombosis at admission to inpatient rehabilitation. Am J Phys Med Rehabil2018; 97(10): 747–753.
65.
KellyBMYoderBMTangCT, et al.Venous thromboembolic events in the rehabilitation setting. PM&R2010; 2(7): 647–663.
66.
DorrisJLNeelySTerhorstL, et al.Effects of music participation for mild cognitive impairment and dementia: a systematic review and meta-analysis. J Am Geriatr Soc2021; 69(9): 2659–2667.
67.
ChenXLiuFLinS, et al.Effects of virtual reality rehabilitation training on cognitive function and activities of daily living of patients with poststroke cognitive impairment: a systematic review and meta-analysis. Arch Phys Med Rehabil2022; 103(7): 1422–1435.
68.
De-Bernardi-OjuelLTorres-ColladoLGarcía-de-la-HeraM. Occupational therapy interventions in adults with multiple sclerosis or amyotrophic lateral sclerosis: a scoping review. Int J Environ Res Publ Health2021; 18(4): 1432.
69.
BrickRPadgettLJonesJ, et al.The influence of telehealth-based cancer rehabilitation interventions on disability: a systematic review. J Cancer Surviv2023; 12: 1725–1750. Available from:https://link.springer.com/10.1007/s11764-022-01181-4
70.
MurphySLPooleJLChenYT, et al.Rehabilitation interventions in systemic sclerosis: a systematic review and future directions. Arthritis Care Res2022; 74(1): 59–69.
71.
ZuoYNavazSLiangW, et al.Prevalence of antiphospholipid antibodies and association with incident cardiovascular events. JAMA Netw Open2023; 6(4): e236530.
72.
Nguyen-OghalaiTUWuHMcNearneyTA, et al.Functional outcome after stroke in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum2008; 59(7): 984–988.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
